Lead Product(s) : Belnacasan
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A team of researchers from the university of Alberta have identified a drug called VX-765 as a strong candidate therapy for MS patients.
Brand Name : VX-765
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 03, 2020
Lead Product(s) : Belnacasan
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?